These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 16337744

  • 1. Cyclooxygenase-2 in hepatocellular carcinoma.
    Wu T.
    Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
    [Abstract] [Full Text] [Related]

  • 2. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.
    Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM.
    Carcinogenesis; 2008 Aug; 29(8):1639-47. PubMed ID: 18579559
    [Abstract] [Full Text] [Related]

  • 3. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
    Berasain C, Castillo J, Prieto J, Avila MA.
    Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
    [Abstract] [Full Text] [Related]

  • 4. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
    Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF.
    Ann Surg Oncol; 2007 Feb; 14(2):752-8. PubMed ID: 17146741
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
    Nagahara T, Okano J, Murawaki Y.
    Oncol Rep; 2007 Nov; 18(5):1281-90. PubMed ID: 17914586
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
    Wu T.
    Biochim Biophys Acta; 2005 Jul 25; 1755(2):135-50. PubMed ID: 15921858
    [Abstract] [Full Text] [Related]

  • 7. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
    Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, Krammer PH, Schirmacher P, Müller M.
    Cancer Res; 2006 Jul 15; 66(14):7059-66. PubMed ID: 16849551
    [Abstract] [Full Text] [Related]

  • 8. Growth factors as therapeutic targets in HCC.
    Furuse J.
    Crit Rev Oncol Hematol; 2008 Jul 15; 67(1):8-15. PubMed ID: 18434184
    [Abstract] [Full Text] [Related]

  • 9. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct 15; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

  • 10. Attenuation of iNOS in an LPS-stimulated macrophage model by omega-3 fatty acids is independent of COX-2 derived PGE2.
    Razzak A, Aldrich C, Babcock TA, Saied A, Espat NJ.
    J Surg Res; 2008 Apr 15; 145(2):244-50. PubMed ID: 18067925
    [Abstract] [Full Text] [Related]

  • 11. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
    Cui W, Hu SX, Tang ZY, Hu KQ.
    Anticancer Drugs; 2008 Oct 15; 19(9):891-7. PubMed ID: 18766003
    [Abstract] [Full Text] [Related]

  • 12. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Oct 15; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 13. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 14. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
    Lampiasi N, Foderà D, D'Alessandro N, Cusimano A, Azzolina A, Tripodo C, Florena AM, Minervini MI, Notarbartolo M, Montalto G, Cervello M.
    Int J Mol Med; 2006 Feb 01; 17(2):245-52. PubMed ID: 16391822
    [Abstract] [Full Text] [Related]

  • 15. The epidermal growth factor receptor: a link between inflammation and liver cancer.
    Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA.
    Exp Biol Med (Maywood); 2009 Jul 01; 234(7):713-25. PubMed ID: 19429859
    [Abstract] [Full Text] [Related]

  • 16. Dysregulation of growth factor signaling in human hepatocellular carcinoma.
    Breuhahn K, Longerich T, Schirmacher P.
    Oncogene; 2006 Jun 26; 25(27):3787-800. PubMed ID: 16799620
    [Abstract] [Full Text] [Related]

  • 17. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.
    Cancer Lett; 2007 Apr 08; 248(1):32-40. PubMed ID: 16837130
    [Abstract] [Full Text] [Related]

  • 18. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H.
    Oncol Rep; 2007 Feb 08; 17(2):441-6. PubMed ID: 17203185
    [Abstract] [Full Text] [Related]

  • 19. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.
    Mol Carcinog; 2009 Jan 08; 48(1):56-65. PubMed ID: 18506760
    [Abstract] [Full Text] [Related]

  • 20. Systemic therapy for hepatocellular carcinoma.
    Thomas MB.
    Cancer J; 2008 Jan 08; 14(2):123-7. PubMed ID: 18391618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.